Business Context and Reporting Period
Company: MacroGenics, Inc. (MGNX)
Filing Type: Form 8-K (Current Report)
Report Date: August 13, 2026
Reporting Period: Quarter ended June 30, 2026
Context: The filing announces financial and operating results for the second quarter of 2026. The detailed results are contained in a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided text serves as a cover report referencing an attached press release (Exhibit 99.1). It does not contain specific numerical data. Consequently, the filing text does not provide a clear value for:
- Revenue
- Profit or Net Income
- Cash Flow
- Profit Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. Investors must refer to the attached Exhibit 99.1 for comparative analysis.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the announcement of results but does not include specific management commentary, forward-looking guidance, or risk factors within the text of the 8-K itself.
Legal Disclaimer: The information in this filing and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 13, 2026) for actual financial figures.
- Verify specific revenue and cash burn rates for the quarter ended June 30, 2026.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm liquidity runway based on the cash balance reported in the full press release.